Susquehanna International Group
ADAP

Susquehanna International Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Susquehanna International Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,300
Closed -$2.47K – 12246
2025
Q2 		$2.47K Sell
10,300
-5,300
-34% -$1.42K ﹤0.01% 12482
2025
Q1 		$3.12K Sell
15,600
-3,900
-20% -$2.02K ﹤0.01% 12282
2024
Q4 		$10.5K Sell
19,500
-13,200
-40% -$9.62K ﹤0.01% 11980
2024
Q3 		$31.1K Buy
32,700
+21,000
+179% +$23.8K ﹤0.01% 11529
2024
Q2 		$11.3K Buy
+11,700
New +$12.8K ﹤0.01% 11759
2021
Q3 		– Sell
-27,900
Closed -$119K – 12653
2021
Q2 		$119K Sell
27,900
-63,100
-69% -$306K ﹤0.01% 11994
2021
Q1 		$483K Sell
91,000
-38,400
-30% -$220K ﹤0.01% 9550
2020
Q4 		$697K Sell
129,400
-99,000
-43% -$538K ﹤0.01% 7549
2020
Q3 		$1.82M Sell
228,400
-6,800
-3% -$59.5K ﹤0.01% 4797
2020
Q2 		$2.35M Buy
+235,200
New +$1.48M ﹤0.01% 4200
2018
Q4 		– Sell
-99,300
Closed -$1.35M – 8834
2018
Q3 		$1.35M Buy
99,300
+42,900
+76% +$450K ﹤0.01% 4676
2018
Q2 		$669K Buy
56,400
+5,000
+10% +$62.3K ﹤0.01% 6215
2018
Q1 		$577K Buy
51,400
+27,700
+117% +$242K ﹤0.01% 6337
2017
Q4 		$158K Buy
23,700
+13,300
+128% +$103K ﹤0.01% 8453
2017
Q3 		$85K Buy
+10,400
New +$64.9K ﹤0.01% 8411

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's ADAP Position: Q4 2025 in Review

Susquehanna International Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 308,065 shares — an estimated $40K sold.

Susquehanna International Group first reported a position in ADAP in Q4 2015 and held it in 22 quarters. The position peaked at $1.16M in Q3 2021. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Susquehanna International Group reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 308,065 Adaptimmune Therapeutics shares in Q4 2025, an estimated $40K.
  • Susquehanna International Group first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 22 quarters.
  • Susquehanna International Group's Adaptimmune Therapeutics position peaked at $1.16M in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.